Literature DB >> 10382913

Lower limb surgery in Duchenne muscular dystrophy.

J Forst1, R Forst.   

Abstract

Two hundred and thirteen of 428 patients with Duchenne muscular dystrophy (DMD) of a prospective and open study were operated on bilaterally with hip and knee release, aponeurectomy of the iliotibial band and Achilles tendon lengthening. In 87 patients the operation was carried out during early restrictions of the lower limb joint mobility at an average age of 6.56 years (4.02-8.26, SD 1.42). The follow-up was on average 5.4 years (0.25-9.01, SD 2.7). This group was compared to a control group (natural history) consisting of 100 non-operated DMD patients. A significant (P < 0.001) release of the contractures could be obtained. Loss of walking ability occurred in the control group at an average of 9.29 years (5.85-13.63, SD 1.98) and in the operated group at an average of 10.55 years (8.17-14.39, SD 1.76). This shows that early lower limb surgery leads to a prolongation of independent ambulation of 1.25 years on average. In contrast to the patients of the control group all treated patients between ages 6 and 8 years could walk independently. The positive influence of early lower limb surgery could also be shown by the development of Hammersmith motor ability score, CIDD (Council of Investigation of Duchenne Dystrophy) grading and Vignos scale. Nevertheless, in consideration of the well-known course of DMD not only the prolongation of ambulation but also the achieved prolongation of assisted standing ability with no or mild contractures are aims of lower limb surgery. Since no improvement of muscle strength could be observed after lower limb surgery, further studies have to investigate if additionally administered steroids can prolong ambulation after early lower limb surgery.

Entities:  

Mesh:

Year:  1999        PMID: 10382913     DOI: 10.1016/s0960-8966(98)00113-8

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  8 in total

1.  Shifts in macrophage cytokine production drive muscle fibrosis.

Authors:  James G Tidball; Michelle Wehling-Henricks
Journal:  Nat Med       Date:  2015-07       Impact factor: 53.440

2.  [Current strategies of conservative and operative treatment of the most frequent muscular disorders].

Authors:  A Fujak; R Forst; J Forst
Journal:  Orthopade       Date:  2010-01       Impact factor: 1.087

3.  Current treatment and management of dystrophinopathies.

Authors:  Nathalie Goemans; Gunnar Buyse
Journal:  Curr Treat Options Neurol       Date:  2014-05       Impact factor: 3.598

4.  Positive effect of the combination of multilevel contracture release and glucocorticoid treatment in Duchenne muscular dystrophy.

Authors:  Claudia Weiß; Corinna Stoltenburg; Dilan Bayram; Julia Funk; Susanne Lebek
Journal:  J Child Orthop       Date:  2020-08-01       Impact factor: 1.548

5.  Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy.

Authors:  Michelle Wehling-Henricks; Maria C Jordan; Tomomi Gotoh; Wayne W Grody; Kenneth P Roos; James G Tidball
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

6.  Surgical treatment of Duchenne muscular dystrophy patients in Germany: the present situation.

Authors:  Jürgen Forst; Raimund Forst
Journal:  Acta Myol       Date:  2012-05

7.  Ratio of Creatine Kinase to Alanine Aminotransferase as a Biomarker of Acute Liver Injury in Dystrophinopathy.

Authors:  Liang Wang; Menglong Chen; Min Xu; Jing Li; Pinning Feng; Ruojie He; Yuling Zhu; Huan Li; Jinfu Lin; Cheng Zhang
Journal:  Dis Markers       Date:  2018-06-19       Impact factor: 3.434

Review 8.  Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis.

Authors:  Nermina Ferizovic; Jessica Summers; Igor Beitia Ortiz de Zárate; Christian Werner; Joel Jiang; Erik Landfeldt; Katharina Buesch
Journal:  PLoS One       Date:  2022-03-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.